Harbin Medicine major shareholder buys Pfizer Pig vaccine

Under the Ministry of Commerce's antitrust pressure Pfizer Pharmaceutical, finally for its pig Mycoplasma pneumonia vaccine business in China to find a domestic.　　According to media reports, Harbin Pharmaceutical Group's bio-vaccine Company (hereinafter referred to as the Harbin-Pharmaceutical biological vaccine) at a cost of nearly 50 million dollars to obtain the business. For the acquisition, pharmaceutical industry analysts have applauded, saying that Harbin Pharmaceutical group, the money spent value.　　In addition, because of Harbin Pharmaceutical group in the shares of Harbin Medicine (600664, closing price of 21.79 yuan) to make a commitment to inject capital, the industry began to speculate that the new assets are likely to be injected with the Harbin medicine biological vaccine to the listed companies. Or will be injected into the public company Harbin Pharmaceutical shares predecessor is the Harbin Municipal Medical Administration of the 31 state-owned enterprises of Haerbin Pharmaceutical Group, restructured in 1991 to Harbin Pharmaceutical shares, and set up a group of Kazakhstan drug Holdings.　　Company in 1993 listed, 2000 renamed as Harbin Pharmaceutical shares. August 2008, the company completed the split share reform, and promised in the 30 months after the reform (that is, February 2011), Harbin Pharmaceutical Group will inject not less than 2.611 billion yuan of assets and cash assets, roe not less than 11%, and after injection, The weighted average ROE of the shares of Harbin Medicine after deducting non-recurrent gains is no lower than that of the previous year (the 2009 shares Roe was 15.6%).　　The injection must be completed within 36 months (i.e. before August 2011). Needle in the above pledge, GF securities Ge Jing has made the following judgments: Under the ROE index pressure, the cash form is unlikely to be used to expand the assets, and earlier in the group to inject more than expected two assets of the HA pharmaceutical biological vaccine and Harbin Pharmaceutical Group Bioengineering Co., Ltd. distance of 2.6 billion yuan total assets index,　　So the group may acquire other pharmaceutical companies to inject, and the group will make obvious moves this year as the injection plan is to be proposed by February next year.　　As 2010 's time is about to be over, the group is "clicked" with Pfizer, which is eager to resell the pig vaccine business. Pfizer's takeover of another major pharmaceutical giant, Wyeth, is being investigated by multinational authorities, and China's Ministry of Commerce has approved one of the conditions for the merger, is to require Pfizer to divest itself of the two-brand pig Mycoplasma pneumonia vaccine business, which is sold domestically at the Respisure and Rui-Respisureone.　　Media reports said that the intention to sell the business, including the domestic stock (600195, closing price 27.18 yuan) and foreign Novartis and Lilly, but their offer is not Harbin pharmaceutical group "generous." Harbin Pharmaceutical Group spokesman Gao also told the Daily Economic news reporter that the acquisition has been approved by the Ministry of Commerce, the acquisition of the object of the targets of the red-pig mycoplasma pneumonia vaccine in the mainland all intellectual property rights, production technology, product brand, while the offshore part is still retained by Pfizer. Harbin Pharmaceutical Biological vaccine will inherit the two brands in the mainland market business, products will be in the Harbin Pharmaceutical Group bio-pharmaceutical industry base for production and sales. ToWhether the purchase price is 50 million dollars and what further plans are made after the acquisition, Gao also Xiaoerbuda, saying that more answers will be announced at the presentation. Although Harbin Pharmaceutical group did not indicate the intention to inject capital, but a brokerage industry researcher analysis, the Harbin Medicine biological vaccine to buy it, the possibility of expanding the size of assets.　　The total assets of Harbin-administered biological vaccine are now 350 million yuan, and the acquisition can expand the assets of hundreds of millions of yuan.　　Guo Xin Securities congratulate Ping Pigeon analysis, Harbin Pharmaceutical Group also has a total assets of 140 million yuan bioengineering company, registered capital of 50 million yuan of Wuda Lian Chi mineral water and three refined medicine (600829, closing price of 20.75 yuan) 44.82% equity, may inject Harbin medicine shares.　　Industry optimistic about the acquisition of this acquisition will give Harbin Pharmaceutical group how much profit? Harbin Pharmaceutical Group's own evaluation of the acquisition is very high. Group Introduction, the official launch of the International cooperation project, will promote China's veterinary drugs and animal vaccine industry and international standards, open up the development of large-scale pig production in China's new course.　　Lu Ying, the director of the vaccine Division, also told the media that the company was planning to make the Pig Series A key product for 2010. It is reported that porcine Mycoplasma pneumonia in the civil is known as "pig asthma", the incidence rate of more than 90%. Rui-Times Fit series in the domestic sales scale estimated at more than 70 million yuan, gross margin estimates more than the pig foot and mouth disease vaccine.　　In addition, the series of products in the domestic few competitors.　　Jinan Rui Jia Animal Health products Company is one of Pfizer's major agents in China, in an interview with the Daily Economic news, the company's sales manager said that the price and profit of foreign products were significantly higher than those of similar products in the industry, as well as Mr Rui and the two-Mong products.　　Societe Generale Securities Wang Yu told the Daily Economic news reporter, at present, the mandatory immunization vaccine market in the country is basically divided into enterprises such as livestock, and foreign investment in the market-oriented vaccine field has high quality, high price, higher profit characteristics, Harbin Pharmaceutical Group through the acquisition, can be taken to enhance the animal vaccine business, promote performance.　　He also said that through this acquisition, Harbin Pharmaceutical Group's future business will be dominated by traditional brand medicine, the transformation of prescription drugs, OTC, health care products, pharmaceutical business, modern Chinese medicine and biotechnology simultaneously the pattern. Without regard to the premise of injecting assets, Wang Yu gave Harbin Pharmaceutical shares 2010 ~2012 EPS for 0.9 yuan, 1.08 yuan and 1.31 yuan, if 2.6 billion yuan in the capital injection completed next year, the expected performance will increase by about 10%, that is, 2011 EPS rose to 1.2 yuan.